There's a lot going on with biotech giant (NASDAQ: REGN) that may be of interest to investors. The company could soon face biosimilar competition from one of its key growth drivers, Eylea, while it recently received an important regulatory approval from the U.S. Food and Drug Administration (FDA).
Regeneron has trounced the market over the trailing-12-month period, but it's essential to review these developments before buying the company's shares. With that said, let's dig deeper into what's happening with Regeneron and figure out whether it is worth investing in the drugmaker.
Eylea is a medicine for wet age-related macular degeneration (AMD). It has been one of Regeneron's most significant growth drivers for a while now, although it shares the rights to it with Bayer. Regeneron owns exclusive rights to Eylea in the U.S. and is entitled to a percentage of the medicine's revenue outside the country where Bayer markets it.
Source Fool.com